论文部分内容阅读
目的探讨瑞舒伐他汀应用于脑梗死的临床疗效及对肿瘤坏死因子(TNF-α)的影响。方法收集符合纳入标准的脑梗死住院患者资料共100例,根据随机原则平均分为对照组和观察组,每组50例。对照组接受常规治疗方案,观察组在对照组的基础上联合使用瑞舒伐他汀。比较两组治疗总有效率、脑卒中量表(NIHSS)评分及TNF-α水平。结果经过治疗,观察组达到了84.0%的治疗总有效率,明显高于对照组的62.0%,差异有显著性(P<0.05)。入组时,NIHSS评分和TNF-α水平在两组间未表现出差异,经过不同方案治疗,与对照组相比,观察组上述两项指标均显著降低,差异有显著性(P<0.05)。结论瑞舒伐他汀治疗脑梗死效果良好,可以提高治疗有效率,改善神经功能,并减轻炎性反应。
Objective To investigate the clinical effect of rosuvastatin on cerebral infarction and its effect on tumor necrosis factor (TNF-α). Methods A total of 100 hospitalized patients with cerebral infarction who met the inclusion criteria were enrolled. According to the randomized principle, they were divided into control group and observation group with 50 cases in each group. The control group received routine treatment. The observation group was given rosuvastatin on the basis of the control group. The total effective rate, the Stroke Scale (NIHSS) score and the level of TNF-α were compared between the two groups. Results After treatment, the treatment group reached 84.0% of the total effective rate was significantly higher than the control group of 62.0%, the difference was significant (P <0.05). NIHSS score and TNF-α level did not show any significant difference between the two groups at the time of enrollment. Compared with the control group, the two indexes in the observation group were significantly decreased after treatment with different regimens (P <0.05) . Conclusion Rosuvastatin treatment of cerebral infarction with good results, can improve the treatment efficiency, improve nerve function, and reduce the inflammatory response.